Telix Pharmaceuticals | TLX - Operating Expenses


Telix Pharmaceuticals reported AUD405.4M in Operating Expenses for its fiscal semester ending in December of 2025.





Operating Expenses Change Date
Cochlear AUD 914.9M 454.8M Dec/2025
CSL USD 5.7B 2.82B Dec/2025
Integral Diagnostics AUD 219.16M 66.76M Jun/2024
Mayne Pharma AUD 103.54M 9.39M Jun/2024
Medical Developments International AUD 21.61M 11.59M Dec/2025
Mesoblast USD 82.31M 26.16M Dec/2025
Neuren Pharmaceuticals AUD 25.23M 16.54M Dec/2025
Pacific Edge NZD 22.5M 2.84M Jun/2026
Paradigm Biopharmaceuticals AUD 21.85M 13.36M Dec/2025
Polynovo AUD 68.22M 1.24M Dec/2025
PYC Therapeutics AUD 33.63M 14.33M Dec/2025
Ramsay Health Care AUD 8.8B 83.5M Dec/2025
ResMed USD 922.51M 49.28M Dec/2025
Sonic Healthcare AUD 4.23B 2.14B Dec/2024